pedmarqsi
fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - alle anderen therapeutischen produkte - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.
sodium chloride 0,9 % b. braun inf. sol. i.v. vial
sodium chloride 0,9 % b. braun inf. sol. i.v. vial
sodium chloride 0,9 % b. braun inf. sol. i.v. vial
sodium chloride 0,9 % fresenius kabi inf. sol. i.v.
sodium chloride 0,9 % fresenius kabi inf. sol. i.v.
sodium chloride 0,9 % fresenius kabi inf. sol. i.v.
sodium chloride 0,9 % kabipac 0.9 % inf. sol. i.v. vial
sodium chloride 0,9 % kabipac 0.9 % inf. sol. i.v. vial
sodium chloride 0,9 % kabipac 0.9 % inf. sol. i.v. vial